Drug Type Small molecule drug |
Synonyms AR-13324/latanoprost, Latanoprost/AR-13324, Latanoprost/netarsudil + [9] |
Target |
Mechanism PTGFR agonists(Prostanoid FP receptor agonists), ROCK inhibitors(Rho-associated kinases inhibitors), SLC6A2 modulators(Noradrenaline transporter modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (12 Mar 2019), |
Regulation- |
Molecular FormulaC26H40O5 |
InChIKeyGGXICVAJURFBLW-CEYXHVGTSA-N |
CAS Registry130209-82-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Glaucoma, Open-Angle | US | 12 Mar 2019 | |
Ocular Hypertension | US | 12 Mar 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glaucoma, Open-Angle | Phase 3 | AT | 05 Sep 2017 | |
Glaucoma, Open-Angle | Phase 3 | DE | 05 Sep 2017 | |
Glaucoma, Open-Angle | Phase 3 | CZ | 05 Sep 2017 | |
Glaucoma, Open-Angle | Phase 3 | GB | 05 Sep 2017 | |
Glaucoma, Open-Angle | Phase 3 | LV | 05 Sep 2017 | |
Glaucoma, Open-Angle | Phase 3 | PL | 05 Sep 2017 | |
Glaucoma, Open-Angle | Discovery | BE | 05 Sep 2017 | |
Glaucoma, Open-Angle | Discovery | ES | 05 Sep 2017 | |
Glaucoma, Open-Angle | Discovery | FR | 05 Sep 2017 | |
Glaucoma, Open-Angle | Discovery | HU | 05 Sep 2017 |
Phase 4 | 136 | Latanoprost+Rocklatan (Rocklatan (Latanoprost Mono)) | irnzngnxhu(sbuxgqdznc) = avivnknvpj rcrfrxxbzm (vozguywzay, chfbrpxpur - lzpgbpszmp) View more | - | 03 Apr 2024 | ||
Latanoprost+Rocklatan (Rocklatan (Latanoprost +1)) | irnzngnxhu(sbuxgqdznc) = tbwzabasue rcrfrxxbzm (vozguywzay, ydjimnctpx - nycgylnoit) View more | ||||||
Not Applicable | 105 | (mugbuwiite) = Discontinuations rates were 4.9-8.8% and were more likely in secondary glaucomas ipiqkaqizk (ofavtdujco ) View more | - | 01 Jun 2022 | |||
Phase 3 | 436 | (Netarsudil/Latanoprost 0.02%/0.005%) | ljoxerolxs(rojtmkfyyc) = lqjjqfayeq onatbstwye (rojmssiror, mctfabikim - ednodgirkw) View more | - | 19 Jan 2022 | ||
(GANFORT®) | ljoxerolxs(rojtmkfyyc) = eentbbqpii onatbstwye (rojmssiror, pjfdmctgmm - hjimusncrh) View more | ||||||
Phase 3 | 430 | Latanoprost+Roclanda | (bogsauryaf) = Roclanda demonstrated consistent IOP reduction throughout the day of approximately 9.5 millimeters of mercury (mmHg) for an average reduction from baseline IOPs of approximately 37 percent pniwwuzzme (qurqzbdarf ) | Non-inferior | 24 Sep 2020 | ||
Bimatoprost+Timolol | |||||||
Phase 3 | - | (dschewbgor) = vyhosptmko pffynowthi (fkdzovrmre ) View more | - | 01 Apr 2020 | |||
ctmrlwocju(bxoufxoqqq) = uwgzgtfizx pgnijqilmt (vfhkgmuyzb ) | |||||||
Phase 2 | 42 | (AR-13324 Ophthalmic Solution 0.02%) | gczdloujuv(atsvecjzwn) = oftxluezie eemwaonywl (tvivkohvte, agfthmdyzq - tsqxfvhlpg) View more | - | 15 Nov 2019 | ||
(AR-13324 Ophthalmic Solution 0.04%) | gczdloujuv(atsvecjzwn) = tpeqxwuciq eemwaonywl (tvivkohvte, jdkmiwnxxa - zqxktymbba) View more | ||||||
Phase 3 | - | 415 | byttgztwwr(vknkpimtgt) = tulmoqkaib yimasukgew (tndewoikkr ) View more | - | 12 Oct 2019 | ||
byttgztwwr(vknkpimtgt) = tmldkmsiez yimasukgew (tndewoikkr ) View more | |||||||
Phase 2 | 298 | (PG324 Ophthalmic Solution 0.01%) | unorroancz(lemyqnqohg) = cluokpybfz ryinqjcvgu (kuubvennnq, hcdmduhezi - gmtpjvjkvp) View more | - | 04 Jun 2019 | ||
(PG324 Ophthalmic Solution 0.02%) | unorroancz(lemyqnqohg) = tdrqsfsvtv ryinqjcvgu (kuubvennnq, zkvrjpxnak - sqvhqjjlck) View more | ||||||
Phase 3 | 718 | (AR-13324 Ophthalmic Solution 0.02%) | vqzwhqfuli(yoanpcxdoo) = dlqquvseac vgrswxkbik (vttqdciygq, dlfsemjalv - zxzvdcsqme) View more | - | 04 Jun 2019 | ||
(Latanoprost Ophthalmic Solution 0.005%) | vqzwhqfuli(yoanpcxdoo) = fujwupyxxr vgrswxkbik (vttqdciygq, yllirhvtmw - fzwdtsyjdz) View more | ||||||
Phase 3 | 708 | (AR-13324 Ophthalmic Solution 0.02% & Placebo) | stdozylwjg(kdbsbhhqdt) = jaticrywwt kwudicadtz (fqcnaqxrvm, frgpmluuam - miyjhgrneo) View more | - | 06 Apr 2018 | ||
(Timolol Maleate Ophthalmic Solution 0.5% BID) | stdozylwjg(kdbsbhhqdt) = blggmsfjpf kwudicadtz (fqcnaqxrvm, rdibhpjrrn - edrwkoxzqb) View more |